Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma
This phase I trial studies the side effects and best dose of giving bortezomib and romidepsin together in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent B-cell lymphoma, peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Bortezomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma|
- Maximum tolerated dose [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Dose at which no more than 1 dose-limiting toxicity is observed in as many as 6 patients
- Pharmacodynamic responses [ Time Frame: 2 years ] [ Designated as safety issue: No ]To explore candidate pharmacodynamic markers for use in subsequent phase II trials.
|Study Start Date:||April 2010|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
|Experimental: bortezomib + romidepsin||
Starting dose: 1.3 mg/sq m
Other Names:Drug: Romidepsin
Starting dose: 8 mg/sq m
- Determine the maximum tolerated dose (MTD) for the combination of bortezomib and romidepsin administered weekly x 3 every (q) 4wk in patients with CLL/SLL, indolent B-cell lymphoma, PTCL or cutaneous T-cell lymphoma (CTCL).
- Determine safety and tolerance and describe the toxicities of the combination.
- Demonstrate adequate methods for the assessment of pharmacodynamic responses of CLL cells to the combination with respect to effects on NF-kappa B (nuclear RelA and processing of p52 as a marker of p100 processing), expression of the NF-kappa B-dependent proteins XIAP and Bcl-xL, and Bim, and document pharmacodynamic responses observed in the course of this study * Document the pharmacodynamic responses associated with this regimen in these patients.
- Document the anticancer activity of this regimen in these patients.
OUTLINE: Patients receive bortezomib IV over 3-5 seconds and romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood samples from patients with chronic lymphocytic leukemia are collected at baseline and after day 1 of course 1 of study treatment for pharmacodynamic and correlative laboratory studies.
|Contact: Steven Grant, MDemail@example.com|
|Contact: Beata Holkova, MDfirstname.lastname@example.org|
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Not yet recruiting|
|Chicago, Illinois, United States, 60611|
|Contact: Shuo Ma, MD, PhD 312-908-5250 email@example.com|
|Contact: Daniel Larson 312-695-1377 firstname.lastname@example.org|
|Principal Investigator: Shuo Ma, MD, PhD|
|United States, Maryland|
|University of Maryland Greenebaum Cancer Center||Recruiting|
|Baltimore, Maryland, United States, 21201|
|Contact: Pat Lesho 410-328-2577 email@example.com|
|Principal Investigator: Amy Kimball, MD, PhD|
|United States, North Carolina|
|University of North Carolina||Recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|Contact: Thomas C Shea, MD 919-966-7746 firstname.lastname@example.org|
|Contact: Ranju Singh email@example.com|
|Principal Investigator: Thomas C. Shea, MD|
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center, Vanderbilt University||Not yet recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Jessica Piggee 615-875-6120 firstname.lastname@example.org|
|Principal Investigator: Nashitha Reddy, MBBS|
|United States, Virginia|
|Virginia Commonwealth University/Massey Cancer Center||Recruiting|
|Richmond, Virginia, United States, 23298|
|Contact: Beata Holkova, MD 804-628-2581 email@example.com|
|Contact: Mary Beth Tombes, RN, MN 804-628-1357 firstname.lastname@example.org|
|Principal Investigator: Beata Holkova, MD|
|Principal Investigator:||Beata Holkova, MD||Massey Cancer Center|
|Principal Investigator:||Thomas C. Shea, MD||UNC Lineberger Comprehensive Cancer Center|
|Study Chair:||Steven Grant, MD||Virginia Commonwealth University|
|Principal Investigator:||Sho Ma, MD, PhD||Northwestern University & Robert H Lurie Comprehensive Cancer Center|
|Principal Investigator:||Amy Kimball, MD, PhD||University of Maryland Greenebaum Cancer Center|
|Principal Investigator:||Nishitha Reddy, MBBS||Vanderbilt-Ingram Cancer Center, Vanderbilt University|